Arkolith/Insider Trading/PRME/Form 4

Alenson Carman

See RemarksPrime Medicine, Inc. (PRME) · full profile →Form 4 · filed Aug 5, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
0 non-derivative · 8 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 1, 2025Grant(A)90K——90K
Aug 1, 2025Grant(A)90K——90K
Aug 1, 2025Disposed to issuer(D)6K——0
Aug 1, 2025Grant(A)6K——6K
Aug 1, 2025Disposed to issuer(D)90K——0
Aug 1, 2025Grant(A)16K——16K
Aug 1, 2025Disposed to issuer(D)16K——0
Aug 1, 2025Disposed to issuer(D)90K——0

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001894562-25-000042) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML